Li Gao

Li Gao

Auto-generated profile, based on publicly available information

Li Gao

Department of Urology Surgery The Second Affiliated Hospital of Guilin Medical University, Guilin Medical University Guilin China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BLBihui Li
Bihui Li
XZXing Zhang
Xing Zhang
QRQianyao Ren
Qianyao Ren
LGLi Gao
Li Gao
JTJing Tian
Jing Tian
In spite of the promising in vitro and preclinical results, dual PI3K/Akt/mTOR inhibitor NVP-BEZ235, and ATP-competitive mTOR inhibitor PP242 both failed to confirm their inhibitory efficacy against renal cell carcinoma (RCC) in clinical settings. Therefore, a better understanding of the molecular mechanism is essential so as to provide possibilities for their use in combination with other agents. In present study, RCC cell lines (UMRC6, 786-0 and UOK121) were treated with NVP-BEZ235, PP242 or Rapamycin, an mTOR complex 1 (mTORC1)-specific inhibitor. They all suppressed cell proliferation and invasion, induced apoptosis and cell cycle arrest, and the effects were in the order of NVP-BEZ235 > PP242 > Rapamycin. Accordingly, the marked and sustained decrease in speckle-type POZ protein (SPOP) expression and phosphorylation of Akt and mTOR kinases was observed in RCC cells treated with NVP-BEZ235 and PP242, whereas only potent inhibition of mTOR activity was induced in Rapamycin-treated cells. In considering the overactivation of c-Jun and IκB-α in human renal tumor tissue, we next investigated the role of JNK and IKK pathways in the response of RCC cells to these compounds. First of all, transforming growth factor β activated kinase 1 (TAK1)-dependent activation of JNK/ (activator protein-1) AP-1 axis in RCC cells was proved by the repression of AP-1 activity with TAK1 or JNK inhibitor. Second, the profound inhibition of TAK1/JNK/AP-1 pathway was demonstrated in RCC cells treated with NVP-BEZ235 or PP242 but not Rapamycin, which is manifested as a reduction in activity of TAK1, c-Jun and AP-1. Meanwhile, subsequent to TAK1 inactivation, the activation of IκB-α was also reduced by NVP-BEZ235 and PP242. Likewise, in vivo, treatment with NVP-BEZ235 and PP242 suppressed the growth of xenografts generated from 786-0 and A498 cells, along with decreased expression of phospho-TAK1, phospho-c-Jun, and phospho-IκB-α. In contrast, Rapamycin elicited no significant inhibitory effects on tumor growth and phosphorylation of TAK1, c-Jun and IκB-α. We conclude that besides PI3K/Akt/mTOR signaling, NVP-BEZ235, and PP242 simultaneously target TAK1-dependent pathways in RCC cells. Notably, these effects were more marked in the presence of NVP-BEZ235 than PP242, indicating the potential application of NVP-BEZ235 in combination therapy for RCC.

1 June 2021 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
CMChao Mi
Chao Mi
LBLu Bai
Lu Bai
YYYuyang Yang
Yuyang Yang
JDJie Duan
Jie Duan
LGLi Gao
Li Gao

31 March 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
LLLinfeng Li
Linfeng Li
BZBaotong Zhou
Baotong Zhou
HXHaoyang Xu
Haoyang Xu
HSHailin Shi
Hailin Shi
LGLi Gao
Li Gao
BGBo Ge
Bo Ge
Since 2019, coronavirus disease 2019 (COVID-19) has swept the world and become a new virus threatening the health of all mankind. The survey found that prostate cancer accounts for one in three male cancer patients infected with COVID-19. This undoubtedly makes prostate cancer patients face a more difficult situation. Prostate cancer is the second most harmful malignant tumor in men because of its insidious onset, easy metastasis, and easy development into castration-resistant prostate cancer even after treatment. Due to its high immunogenicity and a small number of specific infiltrating T cells with tumor-associated antigens in the tissue, it is difficult to obtain a good therapeutic effect with immune checkpoint blocking therapy alone. Therefore, in the current study, we developed a platform carrying Doxorubicin (DOX)-loaded black phosphate nanometer combined with photothermal therapy (PTT) and found this drug combination stimulated the immungentic cell death (ICD) process in PC-3 cells and DC maturation. More importantly, zinc ions have a good immunomodulatory function against infectious diseases, and can improve the killing ability of the nanosystem against prostate cancer cells. The introduction of Aptamer (Apt) enhances the targeting of the entire nanomedicine. We hope that this excellent combination will lead to effective treatment strategies for prostate cancer patients infected with COVID-19.

4 November 2024 in Food Science & Nutrition
Verified
Journal Article
Open access
QCQingting Chen
Qingting Chen
JMJie Mo
Jie Mo
YLYu Li
Yu Li
LGLi Gao
Li Gao
KWKa Wu
Ka Wu
Cystitis glandularis (CG), known as a pre‐gradual lesion in the bladder, is the pathological changes in the vesical mucosa characterized by inflammatory invasion and chronic obstruction. Clinically, effective treatment against CG is prescribed only when using drug therapy. Fucoidan, the naturally extractive polysaccharide, is well‐reported bioactive compound with anti‐inflammatory and immunoregulatory properties. In this research, an emerging computational approach was applied to explicate anti‐CG actions and pharmacological targets exhibited by fucoidan in detail. Current network pharmacology data showed that 16 intersection genes of fucoidan and CG were identified, whereas all 6 core targets, including interleukin‐6 (IL‐6), tumor necrosis factor (TNF), interleukin‐1B (IL‐1B), matrix metalloproteinase‐9 (MMP‐9), interleukin‐10 (IL‐10), matrix metalloproteinase‐2 (MMP‐2), biological processes, and signaling pathways of fucoidan against CG were characterized, respectively. As revealed in the underlying mechanism, the anti‐CG actions achieved by fucoidan were chiefly implicated in the reduction of inflammatory reactions and enhancement of immunoregulation. Taken together, these network bioinformatics findings may be used to reveal anti‐CG effects and the pharmacological mechanism of fucoidan before further experimental validation. Furthermore, those core genes identified may be therapeutic targets for research and development of fucoidan‐anti‐CG.

2 May 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
HXHaoyang Xu
Haoyang Xu
JLJiaqi Liu
Jiaqi Liu
XLXiangkai Li
Xiangkai Li
JLJiawei Li
Jiawei Li
XLXiao Lin
Xiao Lin
KLKeng Po Lai
Keng Po Lai

21 December 2021 in Research Square
Verified
Preprint
Open access
PDF file
LLLinfeng Li
Linfeng Li
LGLi Gao
Li Gao
HXHaoyang Xu
Haoyang Xu
Prostate cancer is the second most harmful malignant tumor in men because of its insidious onset, easy metastasis, and easy development into castration-resistant prostate cancer even after treatment. Due to its high immunogenicity and a small number of specific infiltrating T cells with tumor-associated antigens in the tissue, it is difficult to obtain a good therapeutic effect with immune checkpoint blocking therapy alone. Therefore, in the current study, we developed a platform carrying Doxorubicin (DOX)-loaded black phosphate nanometer combined with photothermal therapy (PTT) and found this drug combination stimulated the immungentic cell death (ICD) process in PC-3 cells and DC maturation, allowing the DCs to present the related antigens and stimulate the body to produce more of CD8+ T cells, leading to a stronger immune response.More importantly, the introduction of Zn2+ and Aptamer (Apt) improved the prostate cancer cell killing ability of the nanosystem.